Stephen Andrew Welch - 10 Nov 2025 Form 4 Insider Report for Keenova Therapeutics plc

Role
EVP & Head of Spec Generics
Signature
/s/ Mark Tyndall, Attorney-in-Fact
Transactions as of
10 Nov 2025
Transactions value $
$0
Form type
4
Filing time
12 Nov 2025, 20:00:19
Previous filing
04 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Welch Stephen Andrew EVP & Head of Spec Generics 675 MCDONNELL BLVD., HAZELWOOD /s/ Mark Tyndall, Attorney-in-Fact 12 Nov 2025 0001944355

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction Restricted Stock Units Disposed to Issuer $0 +43.8K $0.00 0 10 Nov 2025 Ordinary Shares 43.8K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Stephen Andrew Welch is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 These restricted units were cancelled in connection with the separation of Par Health, Inc. ("Par Health") from the Issuer in exchange for a number of restricted units of Par Health calculated pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

Remarks:

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.